



## **Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018**

February 20, 2018

MONROVIA, Calif., Feb. 20, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and full year 2017 financial results after the market closes on Tuesday, February 27, 2018. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

Xencor, Inc. Logo

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers, and referencing conference ID number 3991218. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at <http://investors.xencor.com/events.cfm>. The webcast will be archived on the company website for 30 days.

### **About Xencor, Inc.:**

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 11 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb@5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb@7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb@14045 in Phase 1 development for acute myeloid leukemia; XmAb@13676 in Phase 1 development for B-cell malignancies; XmAb@18087 in pre-clinical development for the treatment of neuroendocrine tumors; and XmAb@20717 in pre-clinical development for the treatment of multiple cancers. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer Ingelheim. For more information, please visit [www.xencor.com](http://www.xencor.com).

Cision View original content with multimedia:<http://www.prnewswire.com/news-releases/xencor-to-host-fourth-quarter-and-full-year-2017-financial-results-webcast-and-conference-call-on-february-27-2018-300600264.html>

SOURCE Xencor, Inc.

Investor Contact: John Kuch, Vice President Finance, Xencor, Tel: 626-737-8013, [jkuch@xencor.com](mailto:jkuch@xencor.com); Corporate Communications Contact: Jason I. Spark, Canale Communications for Xencor, Tel: 619-849-6005, [jason@canalecomm.com](mailto:jason@canalecomm.com)